[net-gold] BIOLOGY: Virus-Like Particle Vaccine Protects Monkeys From Chikungunya Virus
- From: "David P. Dillard" <jwne@xxxxxxxxxx>
- To: Net-Gold <Net-Gold@xxxxxxxxxxxxxxx>, Temple University Net-Gold Archive <net-gold@xxxxxxxxxxxxxxxxxxx>, Temple Gold Discussion Group <TEMPLE-GOLD@xxxxxxxxxxxxxxxxxxx>, Net-Gold <net-gold@xxxxxxxxxxxxxxxx>, Sean Grigsby <myarchives1@xxxxxxxxxxxxxxx>, Educator Gold <Educator-Gold@xxxxxxxxxxxxxxx>, Educator Gold <Educator-Gold@xxxxxxxxxxxxxxxx>, K12AdminLIFE <K12AdminLIFE@xxxxxxxxxxxxxxx>, Net-Platinum <net-platinum@xxxxxxxxxxxxxxx>, Net-Gold Nabble <ml-node+3172864-337556105@xxxxxxxxxxxxx>, MediaMentor <mediamentor@xxxxxxxxxxxxxxx>, Digital Divide Diversity MLS <mls-digitaldivide@xxxxxxxxxxxxxxx>, net-gold@xxxxxxxxxxxxx
- Date: Fri, 5 Feb 2010 14:54:37 -0500 (Eastern Standard Time)
.
BIOLOGY:
Virus-Like Particle Vaccine
Protects Monkeys From Chikungunya Virus
Date: Thu, 28 Jan 2010 15:47:46 -0500
From: "NIH OLIB (NIH/OD)" <olib@xxxxxxxxxx>
To: NIHPRESS@xxxxxxxxxxxx
Subject: Virus-Like Particle Vaccine
Protects Monkeys From Chikungunya Virus
U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH NIH News
National Institute of Allergy and Infectious Diseases (NIAID)
<http://www.niaid.nih.gov/>
For Immediate Release: Thursday, January 28, 2010
MEDIA CONTACT: NIAID Office of Communications, 301-402-1663
<e-mail: niaidnews@xxxxxxxxxxxxx>
VIRUS-LIKE PARTICLE VACCINE PROTECTS
MONKEYS FROM CHIKUNGUNYA VIRUS
An experimental vaccine developed using non-infectious virus-like
particles (VLP) has protected macaques and mice against chikungunya virus,
a mosquito-borne pathogen that has infected millions of people in Africa
and Asia and causes debilitating pain, researchers at the National
Institutes of Health have found.
Scientists at the National Institute of Allergy and Infectious Diseases
(NIAID) developed the vaccine because there is no vaccine or treatment for
chikungunya virus infection. Details about the vaccine were published
today in the online version of Nature Medicine.
"Increases in global travel and trade, and possibly climate change, may be
contributing to the spread of disease-carrying mosquitoes into new areas,"
says NIAID Director Anthony S. Fauci, M.D. "Finding safe and effective
human vaccines for chikungunya virus and other insect-borne pathogens is
an important global health priority."
To develop the vaccine, scientists in NIAID's Vaccine Research Center
(VRC) identified the proteins that give rise to chikungunya VLPs. The VLPs
mimic actual virus particles but cannot cause infection, so they can be
used safely as a vaccine to elicit immune responses. The researchers
immunized rhesus macaques with the VLPs, waited 15 weeks before exposing
the animals to chikungunya virus, and observed that the vaccine provided
complete protection from infection.
When the group found that antibodies were responsible for immune
protection, they transferred antibody-containing serum from the vaccinated
macaques to mice with deficient immune systems. The mice then were exposed
to a lethal dose of chikungunya virus, but the immune serum protected them
from infection.
"This virus-like particle vaccine provides a promising way to protect
against an emerging infectious disease threat," says VRC Director Gary
Nabel, M.D., Ph.D. "This same approach could possibly extend to viruses
related to chikungunya that cause fatal diseases such as encephalitis."
Dr. Nabel says his group plans to seek approval for clinical trials to
further evaluate the safety and efficacy of the vaccine in humans.
There are two VLP vaccines for other diseases approved by the Food and
Drug Administration: one for hepatitis B and one for human papillomavirus.
This study marks the first time that scientists have used VLPs in a
vaccine to protect against chikungunya virus, which is in the genus
Alphavirus. The group plans to determine whether VLPs will work against
other alphaviruses, such as Western and Eastern equine encephalitis virus
found in the United States and o'nyong-nyong virus found in Africa.
Investigators from Purdue University, the University of Texas Medical
Branch at Galveston, and Bioqual Inc., in Rockville, Md., collaborated
with NIAID scientists on this study.
NIAID conducts and supports research - at NIH, throughout the United
States, and worldwide - to study the causes of infectious and
immune-mediated diseases, and to develop better means of preventing,
diagnosing and treating these illnesses. News releases, fact sheets and
other NIAID-related materials are available on the NIAID Web site at
<http://www.niaid.nih.gov>
The National Institutes of Health (NIH) -- The Nation's Medical Research
Agency -- includes 27 Institutes and Centers and is a component of the
U.S. Department of Health and Human Services. It is the primary federal
agency for conducting and supporting basic, clinical and translational
medical research, and it investigates the causes, treatments, and cures
for both common and rare diseases. For more information about NIH and its
programs, visit <www.nih.gov>.
##
This NIH News Release is available online at:
<http://www.nih.gov/news/health/jan2010/niaid-28.htm>
Sincerely,
David Dillard
Temple University
(215) 204 - 4584
jwne@xxxxxxxxxx
<http://daviddillard.businesscard2.com>
Net-Gold
<http://groups.yahoo.com/group/net-gold>
Index: <http://tinyurl.com/myxb4w>
<http://listserv.temple.edu/archives/net-gold.html>
<http://groups.google.com/group/net-gold?hl=en>
General Internet & Print Resources
<http://guides.temple.edu/general-internet>
COUNTRIES
<http://guides.temple.edu/general-country-info>
EMPLOYMENT
<http://guides.temple.edu/EMPLOYMENT>
TOURISM
<http://guides.temple.edu/tourism>
DISABILITIES
http://guides.temple.edu/DISABILITIES
INDOOR GARDENING
<http://tech.groups.yahoo.com/group/IndoorGardeningUrban/>
Educator-Gold
<http://groups.yahoo.com/group/Educator-Gold/>
K12ADMINLIFE
<http://groups.yahoo.com/group/K12AdminLIFE/>
RUSSELL CONWELL CENTER SUBJECT GUIDE
http://guides.temple.edu/Russell-Conwell-Center
THE COLLEGE LEARNING CENTER
<http://tinyurl.com/yae7w79>
Nina Dillard's Photographs on Net-Gold
<http://tinyurl.com/36qd2o>
Net-Gold Membership Required to View Photos
Twitter: davidpdillard
Bushell, R. & Sheldon, P. (eds),
Wellness and Tourism: Mind, Body, Spirit,
Place, New York: Cognizant Communication Books.
Wellness Tourism: Bibliographic and Webliographic Essay
David P. Dillard
<http://tinyurl.com/p63whl>
<http://tinyurl.com/ou53aw>
INDOOR GARDENING
Improve Your Chances for Indoor Gardening Success
http://tech.groups.yahoo.com/group/IndoorGardeningUrban/
http://groups.google.com/group/indoor-gardening-and-urban-gardening
http://indoorgardening.jiglu.com/
SPORT-MED
https://www.jiscmail.ac.uk/lists/sport-med.html
http://sportmed.jiglu.com/
http://groups.google.com/group/sport-med
http://groups.yahoo.com/group/sports-med/
http://listserv.temple.edu/archives/sport-med.html
Health Diet Fitness Recreation Sports Tourism
http://health.groups.yahoo.com/group/healthrecsport/
http://groups.google.com/group/healthrecsport
http://healthrecsport.jiglu.com/
health-recreation-sports-tourism@xxxxxxxxxxxxxxxxxxx
Please Ignore All Links to JIGLU
in search results for Net-Gold and related lists.
The Net-Gold relationship with JIGLU has
been terminated by JIGLU and these are dead links.
http://groups.yahoo.com/group/Net-Gold/message/30664
http://health.groups.yahoo.com/group/healthrecsport/message/145
.
Other related posts:
- » [net-gold] BIOLOGY: Virus-Like Particle Vaccine Protects Monkeys From Chikungunya Virus - David P. Dillard
